Research Summary

Measurement-Based Care Speeds Depression Response, Remission in Randomized Trial

Edited by:
Kate Young

Key Highlights:

  • Measurement-based care (MBC) halved time to response and remission versus standard care in adults with major depressive disorder.
  • Median time to response was 2 weeks with MBC vs 4 weeks with standard care; remission occurred at 4 vs 8 weeks.
  • No significant differences in response or remission rates were observed at 24 weeks.
  • Adverse effects and treatment discontinuation rates were similar between groups.

PUPC ad

A multicenter randomized clinical trial conducted in Pakistan found that measurement-based care significantly accelerated symptom improvement in adults with major depressive disorder (MDD) compared with standard care. Published in JAMA Network Open, the study demonstrated that structured monitoring of symptoms and adverse effects can shorten time to both response and remission in a low- and middle-income country (LMIC) setting.

Researchers conducted an assessor-blinded, parallel-arm trial across seven Pakistani cities between September 2022 and January 2024, enrolling 154 adults with nonpsychotic MDD. Participants were randomized 1:1 to receive either MBC or standard care and followed for 24 weeks. Both groups received pharmacotherapy with paroxetine or mirtazapine, while the MBC group underwent regular assessments using validated tools—the Quick Inventory of Depressive Symptomatology–Self-Report and the Frequency, Intensity, and Burden of Side Effects Rating Scale—to guide dose adjustments or medication changes. Standard care relied solely on clinician judgment without structured measurement.

Study Findings

The trial met its primary endpoints, showing significantly faster improvement in the MBC group. Median time to response—defined as a 50% reduction in Hamilton Depression Rating Scale (HDRS-17) scores—was 2 weeks (IQR, 2-4) with MBC compared with 4 weeks (IQR, 2-12) in the standard care group. Similarly, median time to remission (HDRS-17 score ≤7) was 4 weeks (IQR, 4-8) vs 8 weeks (range, 2 weeks to no remission), respectively. These differences were statistically significant, with hazard ratios of 1.53 (95% CI, 1.06-2.20) for response and 1.80 (95% CI, 1.21-2.68) for remission.

At 24 weeks, however, overall response rates were similar between groups (89.1% for MBC vs 86.6% for standard care), as were remission rates (73.4% vs 62.7%). Mean reductions in HDRS-17 scores were modestly greater in the MBC group (−18.1 vs −17.0 points). The MBC group also received higher antidepressant doses and had more frequent clinic visits during early treatment, without increased adverse effects or discontinuation.

Clinical Implications

According to the study authors, the findings suggest that MBC can accelerate time to response and remission in MDD and may be particularly valuable in low-resource settings where timely improvement is critical. The structured monitoring approach may help overcome inadequate dosing and clinical inertia, contributing to faster early outcomes.

The study has limitations, including the use of only paroxetine and mirtazapine, which may limit generalizability to broader prescribing practices. Furthermore, the sample size was powered based on remission rates rather than primary time-to-event outcomes.

Expert Commentary

“Given its scalable nature, MBC offers a viable solution to the need for effective mental health interventions in LMICs, where resources are often constrained and populations face substantial barriers to accessing mental health care. Future studies need to confirm the clinical effectiveness of MBC and assess its cost-effectiveness across various LMICs,” the researchers concluded.

Reference
Husain MI, Nigah Z, Ansari SUH, et al. Measurement-based care to enhance antidepressant treatment outcomes in major depressive disorder: a randomized clinical trial. JAMA Netw Open. 2025;8(9):e2529427. doi:10.1001/jamanetworkopen.2025.29427